China Innovation Policy Reform Streamlines Trial Management
China's latest initiative to establish an innovation ecosystem replaces clinical trial site pre-certification with registration; also included are provisions allowing use of foreign data, strengthening data protection and providing conditional approvals of rare disease treatments.
You may also be interested in...
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
The US/Chinese biotech expects speedier approval of its lead asset plinabulin in China thanks to the government's new drug approval policy.
The approval of Kite's Yescarta has ignited Chinese drug maker Fosun. With a joint venture with Kite in place, the Shanghai conglomerate is looking to accelerate CAR-T development in China despite approval pathway uncertainty.